TIGIT and PD-L1 co-blockade promotes clonal expansion of antitumor T cells by Enchancing Co-stimulation
Anirban Maitra, Professor of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center, shared a recent article by Katherine Nutsch on X:
“The preclinical-clinical chasm for TIGIT is only matched by CD47 I think.
Yesterday, Ira Mellman (ex-Genentech) had a very nice Nature Cancer paper, just months after Roche had another TIGIT phase 3 failure, and the same day Merck threw in the towel on their TIGIT asset.”
Authors: Katherine Nutsch, Karl L Banta, Thomas D Wu, Charles W Tran, Stephanie Mittman, Ellen Duong, Barzin Y Nabet, Yan Qu, Katherine Williams, Sören Müller, Namrata S Patil, Eugene Y Chiang and Ira Mellman
Not an immunologist but the lack of activity across >1 TIGIT antibody points to a fundamental flaw in the biology of how we are targeting this molecule, rather than any one asset. Let’s see how the remaining companies (Arcus) do.
Dr. Anirban Maitra serves as Professor of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center since August 2013, and directs the Sheikh Ahmed Pancreatic Cancer Research Center. He leads an NCI-funded laboratory dedicated to pancreatic cancer research, focusing on genetics and molecular pathology in human and mouse models. His research aims to advance early detection and interception strategies to enhance patient survival rates in pancreatic cancer.
More posts featuring Anirban Maitra.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023